IsoPlexis Corporation

NASDAQ: ISO · Real-Time Price · USD
0.76
-0.00 (-0.21%)
At close: Mar 20, 2023, 9:00 PM

Company Description

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level.

It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services.

The company was incorporated in 2013 and is based in Branford, Connecticut.

IsoPlexis Corporation
IsoPlexis Corporation logo
Country United States
IPO Date Oct 8, 2021
Industry Medical - Devices
Sector Healthcare
Employees 290
CEO Sean Mackay

Contact Details

Address:
35 NE Industrial Road
Branford, Connecticut
United States
Website https://isoplexis.com

Stock Details

Ticker Symbol ISO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001615055
CUSIP Number 465005106
ISIN Number US4650051067
Employer ID 46-2179799
SIC Code 3826

Key Executives

Name Position
Sean Mackay Co-Founder, Chief Executive Officer, Pres & Director
John R. Strahley CPA Chief Financial Officer
Anthony Catalano Senior Vice President of Operations
Carrie Carter Senior Vice President of People Operations
Jing Zhou M.D., Ph.D. Chief Scientific Officer
Rajesh T. Khakhar Vice President of Fin. & Principal Accounting Officer
Richard W. Rew II Senior Vice President, Gen. Counsel & Sec.
Rong Fan Co-Founder & Chairman of Scientific Advisory Board
Verna Siu Senior Vice President of Sales Operations

Latest SEC Filings

Date Type Title
Jun 15, 2023 SC 13D/A [Amend] Filing
Mar 31, 2023 15-12G Filing
Mar 22, 2023 8-K Current Report
Mar 21, 2023 S-8 POS Filing
Mar 21, 2023 S-8 POS Filing
Mar 21, 2023 4 Filing
Mar 21, 2023 4 Filing
Mar 21, 2023 4 Filing
Mar 21, 2023 4 Filing
Mar 21, 2023 4 Filing